Muscular Dystrophy Association Conference 2025 (MDA)

Back

Safety and Efficacy of DYNE-101 in Adults With DM1: Phase 1/2 ACHIEVE Trial Data (poster)

Safety and Efficacy of DYNE-101 in Adults with DM1: Phase 1/2 ACHIEVE Trial Data (presentation)

Safety and Efficacy from the Ongoing Phase 1/2 DELIVER Trial of DYNE-251 in Males with DMD Mutations Amenable to Exon 51 Skipping (poster)

Safety and efficacy from the ongoing Phase 1/2 DELIVER trial of DYNE-251 in males with DMD mutations amenable to exon 51 skipping (presentation)

The FORCETM Platform Enables TfR1-Mediated Delivery of Exon Skipping PMO to the CNS and Resolves Anxiety in a Mouse Model of DMD (poster)

The FORCETM Platform Achieves Robust and Durable DUX4 Suppression and Improves Muscle Function in a Facioscapulohumeral Muscular Dystrophy Mouse Mode (poster)

Characteristics of Patients with Myotonic Dystrophy Type 1 with Complex Care Needs: Results from the Real-World IMPaCT Study (poster)